ERBB2 and gastric cancer: However, several HER2-targeting agents other than trastuzumab, including lapatinib, pertuzumab, and trastuzumab-emtansine, used as first- or second-line treatments failed to improve clinical outcomes in HER2+ GC patients [79,80].